Amarin Corporation plc has announced an exclusive long-term license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA® (icosapent ethyl) across 59 European countries. This strategic partnership aims to enhance the reach and impact of VAZKEPA for patients at risk of cardiovascular events. By aligning with Recordati, Amarin plans to streamline its global operations, resulting in approximately $70 million in cost savings over the next 12 months and accelerating its path to positive cash flow. The agreement signifies a pivotal step in maximizing shareholder value and expanding the product's international presence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.